Dr. Rick Bright Biography-Wiki
Dr. Rick Brightis an American Physician, public health official, and infectious disease expert. He is best known as the former director of the Biomedical Advanced Research and Development Authority.
At the Centers for Disease Control and Prevention Bright spent a decade in vaccine and therapeutics development. Bright also served as the Director of Immunology at Altea Therapeutics and Vice President of Research and Development and Global Influenza Programs at Novavax, Inc while Working in the biotechnology industry,
Bright joined BARDA (he Biomedical Advanced Research and Development Authority )in 2010 and was the Director of the Influenza and Emerging Infectious Diseases Division in the Influenza Division International Program. Bright succeeded founding director Robin Robinson as director of BARDA In late 2016. In the midst of the COVID-19 pandemic, Bright was reassigned to the National Institutes of Health In April 2020.
Dr. Rick Bright Age
Details regarding exactly where and when Dr.Rick was born are unknown to the general public we will update when accurate information is available.
Dr. Rick Bright Height
Bright stands at a fair height and has a fair body weight to match his height. Details regarding his exact measurements are still under investigation with very little known about them. We are keeping close tabs on Rick and will update when accurate information is available.
Dr. Rick Bright Education
For his education, ick received his BS in Biology (Medical Technology) and Physical Sciences from Auburn University in Auburn, Alabama. He also received his Ph.D. in Immunology and Molecular Pathogenesis from Emory University in Atlanta, Georgia.
Emory University is an American private research university in Atlanta, Georgia, the United States founded in 1836 in Oxford, Georgia by the Methodist Episcopal Church. as Emory College in honor of Methodist bishop John Emory.
The institution has nine academic divisions: Nell Hodgson Woodruff School of Nursing, Rollins School of Public Health, the Candler School of Theology Emory College of Arts and Sciences, Oxford College, Goizueta Business School, Laney Graduate School, School of Law, School of Medicine.
Dr. Rick Bright Family
Details regarding who and where his parents and siblings are is unknown to the general public will update when accurate information is available.
Dr. Rick Bright Wife
Dr. Rick has managed to keep information regarding his personal life and it is not known if he is married or not.
Dr. Rick Bright Salary
Information regarding Rick’s salary is still under investigation we will update when accurate information is available. Though the average salary for “public health” ranges from approximately $40,356 yearly for Research Assistant to $95,236 yearly for Director.
Dr. Rick Bright Networth
His exact Networth is still under review we will update when accurate information is available.
Dr. Rick Bright BARDA
in 2010 Rick Bright joined BARDA to lead the BARDA Influenza Division International Program. BARDA was about supporting programs to build and enhance the global capacity for influenza vaccine production and evaluation in developing countries.
Currently, Rick is an international subject matter expert on influenza, vaccines, and therapeutics development and diagnostic programs.
Dr. Rick Bright Vaccine Career
Rick began his career in influenza vaccine and therapeutics development at the U.S. Centers for Disease Control and Prevention, Influenza Division.
Bright focused on avian and human viruses from multiple perspectives including immunology and vaccine development at the CDC. Viral pathogenesis, molecular correlates of pathogenicity, and antiviral drugs were also his other fields of concern.
Dr. Rick Bright Transfer
Rick Bright was abruptly dismissed fro his post as director of the Biomedical Advanced Research and Development Authority, On April 22, 2020, after he clashed with the administration on coronavirus treatments.
In a statement, released by Bright believes his transfer was due to his “insistence that the government invest the billions of dollars allocated by Congress to address the COVID-19 pandemic into safe and scientifically vetted solutions, and not in drugs, vaccines and other technologies that lack scientific merit.”